Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

In Vitro Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam against OXA-48-Carrying Enterobacteriaceae Isolated as Part of the International Network for Optimal Resistance Monitoring (INFORM) Global Surveillance Program from 2012 to 2015.

Kazmierczak KM, Bradford PA, Stone GG, de Jonge BLM, Sahm DF.

Antimicrob Agents Chemother. 2018 Nov 26;62(12). pii: e00592-18. doi: 10.1128/AAC.00592-18. Print 2018 Dec.

PMID:
30249690
2.

Genomic characterization of IMP and VIM carbapenemase-encoding transferable plasmids of Enterobacteriaceae.

Matsumura Y, Peirano G, Bradford PA, Motyl MR, DeVinney R, Pitout JDD.

J Antimicrob Chemother. 2018 Nov 1;73(11):3034-3038. doi: 10.1093/jac/dky303.

PMID:
30099521
3.

A Systematic Approach to the Selection of the Appropriate Avibactam Concentration for Use with Ceftazidime in Broth Microdilution Susceptibility Testing.

Bradford PA, Huband MD, Stone GG.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e00223-18. doi: 10.1128/AAC.00223-18. Print 2018 Jul.

PMID:
29735568
4.

In Vitro Activity of Ceftazidime-Avibactam against Isolates from Patients in a Phase 3 Clinical Trial for Treatment of Complicated Intra-abdominal Infections.

Stone GG, Newell P, Bradford PA.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e02584-17. doi: 10.1128/AAC.02584-17. Print 2018 Jul.

PMID:
29686147
5.

Molecular β-lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials (RECAPTURE 1 and 2) for complicated urinary tract infections: Efficacies analysed against susceptible and resistant subsets.

Mendes RE, Castanheira M, Woosley LN, Stone GG, Bradford PA, Flamm RK.

Int J Antimicrob Agents. 2018 Aug;52(2):287-292. doi: 10.1016/j.ijantimicag.2018.04.001. Epub 2018 Apr 11.

PMID:
29654893
6.

In Vitro Activity of Aztreonam-Avibactam against Enterobacteriaceae and Pseudomonas aeruginosa Isolated by Clinical Laboratories in 40 Countries from 2012 to 2015.

Karlowsky JA, Kazmierczak KM, de Jonge BLM, Hackel MA, Sahm DF, Bradford PA.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00472-17. doi: 10.1128/AAC.00472-17. Print 2017 Sep.

7.

Genomic epidemiology of global VIM-producing Enterobacteriaceae.

Matsumura Y, Peirano G, Devinney R, Bradford PA, Motyl MR, Adams MD, Chen L, Kreiswirth B, Pitout JDD.

J Antimicrob Chemother. 2017 Aug 1;72(8):2249-2258. doi: 10.1093/jac/dkx148.

8.
9.

Importance of Clonal Complex 258 and IncFK2-like Plasmids among a Global Collection of Klebsiella pneumoniae with blaKPC.

Peirano G, Bradford PA, Kazmierczak KM, Chen L, Kreiswirth BN, Pitout JD.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e02610-16. doi: 10.1128/AAC.02610-16. Print 2017 Apr.

10.

In vitro activity of ceftazidime/avibactam against urinary isolates from patients in a Phase 3 clinical trial programme for the treatment of complicated urinary tract infections.

Stone GG, Bradford PA, Yates K, Newell P.

J Antimicrob Chemother. 2017 May 1;72(5):1396-1399. doi: 10.1093/jac/dkw561.

PMID:
28088768
11.
12.

Effect of Susceptibility Testing Conditions on the In Vitro Antibacterial Activity of ETX0914.

Giacobbe RA, Huband MD, deJonge BL, Bradford PA.

Diagn Microbiol Infect Dis. 2017 Feb;87(2):139-142. doi: 10.1016/j.diagmicrobio.2016.03.007. Epub 2016 Mar 8.

PMID:
27856046
13.

Global Escherichia coli Sequence Type 131 Clade with blaCTX-M-27 Gene.

Matsumura Y, Pitout JD, Gomi R, Matsuda T, Noguchi T, Yamamoto M, Peirano G, DeVinney R, Bradford PA, Motyl MR, Tanaka M, Nagao M, Takakura S, Ichiyama S.

Emerg Infect Dis. 2016 Nov;22(11):1900-1907. doi: 10.3201/eid2211.160519.

14.

New Antimicrobial Agents  …  but No Susceptibility Tests!

Ambler JE, Krause KM, Steenbergen JN, Scangarella-Oman NE, Miller LA, Bhagwat SS, Serio AW, Chesnel L, Mahoney NM, Motyl MR, Critchley IA, Iaconis JP, Stone GG, Alder J, Xerri L, McCurdy SP, van Veenhuyzen DF, Grossman T, Echols RM, Williams G, Bradford PA.

Clin Infect Dis. 2016 Dec 1;63(11):1530-1531. Epub 2016 Aug 31. No abstract available.

PMID:
27581762
15.

Structural and sequence analysis of class A β-lactamases with respect to avibactam inhibition: impact of Ω-loop variations.

Lahiri SD, Bradford PA, Nichols WW, Alm RA.

J Antimicrob Chemother. 2016 Oct;71(10):2848-55. doi: 10.1093/jac/dkw248. Epub 2016 Jul 7.

PMID:
27402011
16.

β-Lactams and β-Lactamase Inhibitors: An Overview.

Bush K, Bradford PA.

Cold Spring Harb Perspect Med. 2016 Aug 1;6(8). pii: a025247. doi: 10.1101/cshperspect.a025247. Review.

17.

Comment on: Resistance gene naming and numbering: is it a new gene or not?

Jacoby GA, Bonomo RA, Bradford PA, Bush K, Doi Y, Feldgarden M, Haft D, Klimke W, Nordmann P, Palzkill T, Poirel L, Prasad A, Rossolini GM, Walsh T.

J Antimicrob Chemother. 2016 Sep;71(9):2677-8. doi: 10.1093/jac/dkw204. Epub 2016 Jun 3. No abstract available.

18.

Global Dissemination of blaKPC into Bacterial Species beyond Klebsiella pneumoniae and In Vitro Susceptibility to Ceftazidime-Avibactam and Aztreonam-Avibactam.

Kazmierczak KM, Biedenbach DJ, Hackel M, Rabine S, de Jonge BL, Bouchillon SK, Sahm DF, Bradford PA.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):4490-500. doi: 10.1128/AAC.00107-16. Print 2016 Aug.

19.

Correlation of β-Lactamase Production and Colistin Resistance among Enterobacteriaceae Isolates from a Global Surveillance Program.

Bradford PA, Kazmierczak KM, Biedenbach DJ, Wise MG, Hackel M, Sahm DF.

Antimicrob Agents Chemother. 2015 Dec 14;60(3):1385-92. doi: 10.1128/AAC.01870-15.

20.

Multiyear, Multinational Survey of the Incidence and Global Distribution of Metallo-β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa.

Kazmierczak KM, Rabine S, Hackel M, McLaughlin RE, Biedenbach DJ, Bouchillon SK, Sahm DF, Bradford PA.

Antimicrob Agents Chemother. 2015 Dec 7;60(2):1067-78. doi: 10.1128/AAC.02379-15. Print 2016 Feb.

21.

In Vitro Activity of AZD0914, a Novel Bacterial DNA Gyrase/Topoisomerase IV Inhibitor, against Clinically Relevant Gram-Positive and Fastidious Gram-Negative Pathogens.

Biedenbach DJ, Huband MD, Hackel M, de Jonge BL, Sahm DF, Bradford PA.

Antimicrob Agents Chemother. 2015 Oct;59(10):6053-63. doi: 10.1128/AAC.01016-15. Epub 2015 Jul 20.

22.

Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam.

Singh R, Kim A, Tanudra MA, Harris JJ, McLaughlin RE, Patey S, O'Donnell JP, Bradford PA, Eakin AE.

J Antimicrob Chemother. 2015 Sep;70(9):2618-26. doi: 10.1093/jac/dkv132. Epub 2015 May 29.

PMID:
26024868
23.

In vitro activity of aztreonam-avibactam against a global collection of Gram-negative pathogens from 2012 and 2013.

Biedenbach DJ, Kazmierczak K, Bouchillon SK, Sahm DF, Bradford PA.

Antimicrob Agents Chemother. 2015 Jul;59(7):4239-48. doi: 10.1128/AAC.00206-15. Epub 2015 May 11.

24.

In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-Negative, and atypical bacteria.

Huband MD, Bradford PA, Otterson LG, Basarab GS, Kutschke AC, Giacobbe RA, Patey SA, Alm RA, Johnstone MR, Potter ME, Miller PF, Mueller JP.

Antimicrob Agents Chemother. 2015 Jan;59(1):467-74. doi: 10.1128/AAC.04124-14. Epub 2014 Nov 10.

25.

Global incidence of carbapenemase-producing Escherichia coli ST131.

Peirano G, Bradford PA, Kazmierczak KM, Badal RE, Hackel M, Hoban DJ, Pitout JD.

Emerg Infect Dis. 2014 Nov;20(11):1928-31. doi: 10.3201/eid2011.141388.

26.

RT-PCR and statistical analyses of adeABC expression in clinical isolates of Acinetobacter calcoaceticus-Acinetobacter baumannii complex.

Ruzin A, Immermann FW, Bradford PA.

Microb Drug Resist. 2010 Jun;16(2):87-9. doi: 10.1089/mdr.2009.0131.

PMID:
20438348
27.

Identification of CTX-M beta-lactamases in Escherichia coli from hospitalized patients and residents of long-term care facilities.

Urban C, Mariano N, Bradford PA, Tuckman M, Segal-Maurer S, Wehbeh W, Grenner L, Colon-Urban R, Johnston B, Johnson JR, Rahal JJ.

Diagn Microbiol Infect Dis. 2010 Apr;66(4):402-6. doi: 10.1016/j.diagmicrobio.2009.11.012.

PMID:
20226330
28.

Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection.

Petersen PJ, Jones CH, Venkatesan AM, Bradford PA.

Antimicrob Agents Chemother. 2009 Apr;53(4):1698-700. doi: 10.1128/AAC.01549-08. Epub 2009 Feb 2.

29.
30.

Identification of plasmid-mediated AmpC beta-lactamases in Escherichia coli, Klebsiella spp., and proteus species can potentially improve reporting of cephalosporin susceptibility testing results.

Tenover FC, Emery SL, Spiegel CA, Bradford PA, Eells S, Endimiani A, Bonomo RA, McGowan JE Jr.

J Clin Microbiol. 2009 Feb;47(2):294-9. doi: 10.1128/JCM.01797-08. Epub 2008 Nov 26.

31.
32.

Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.

Petersen PJ, Jones CH, Venkatesan AM, Mansour TS, Projan SJ, Bradford PA.

Antimicrob Agents Chemother. 2009 Feb;53(2):370-84. doi: 10.1128/AAC.01047-08. Epub 2008 Nov 10.

33.

In vitro activity of tigecycline and occurrence of tetracycline resistance determinants in isolates from patients enrolled in phase 3 clinical trials for community-acquired pneumonia.

Bradford PA, Petersen PJ, Tuckman M, Jones CH.

Clin Microbiol Infect. 2008 Sep;14(9):882-6. doi: 10.1111/j.1469-0691.2008.02063.x.

34.

Real-time PCR and statistical analyses of acrAB and ramA expression in clinical isolates of Klebsiella pneumoniae.

Ruzin A, Immermann FW, Bradford PA.

Antimicrob Agents Chemother. 2008 Sep;52(9):3430-2. doi: 10.1128/AAC.00591-08. Epub 2008 Jul 14.

35.

Carbapenem-resistant Escherichia coli harboring Klebsiella pneumoniae carbapenemase beta-lactamases associated with long-term care facilities.

Urban C, Bradford PA, Tuckman M, Segal-Maurer S, Wehbeh W, Grenner L, Colon-Urban R, Mariano N, Rahal JJ.

Clin Infect Dis. 2008 Jun 1;46(11):e127-30. doi: 10.1086/588048.

PMID:
18419424
36.

MarA-mediated overexpression of the AcrAB efflux pump results in decreased susceptibility to tigecycline in Escherichia coli.

Keeney D, Ruzin A, McAleese F, Murphy E, Bradford PA.

J Antimicrob Chemother. 2008 Jan;61(1):46-53. Epub 2007 Oct 29.

PMID:
17967850
37.

Late stage antibacterial drugs in the clinical pipeline.

Projan SJ, Bradford PA.

Curr Opin Microbiol. 2007 Oct;10(5):441-6. Epub 2007 Oct 22. Review.

PMID:
17950658
38.

In vitro antibacterial activities of tigecycline and comparative agents by time-kill kinetic studies in fresh Mueller-Hinton broth.

Petersen PJ, Jones CH, Bradford PA.

Diagn Microbiol Infect Dis. 2007 Nov;59(3):347-9. Epub 2007 Jul 26.

PMID:
17662552
39.

Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline.

Tuckman M, Petersen PJ, Howe AY, Orlowski M, Mullen S, Chan K, Bradford PA, Jones CH.

Antimicrob Agents Chemother. 2007 Sep;51(9):3205-11. Epub 2007 Jul 9.

41.

Validation and reproducibility assessment of tigecycline MIC determinations by Etest.

Bolmström A, Karlsson A, Engelhardt A, Ho P, Petersen PJ, Bradford PA, Jones CH.

J Clin Microbiol. 2007 Aug;45(8):2474-9. Epub 2007 May 23.

42.
43.
44.

Functional, biophysical, and structural bases for antibacterial activity of tigecycline.

Olson MW, Ruzin A, Feyfant E, Rush TS 3rd, O'Connell J, Bradford PA.

Antimicrob Agents Chemother. 2006 Jun;50(6):2156-66.

46.

In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis.

Petersen PJ, Labthavikul P, Jones CH, Bradford PA.

J Antimicrob Chemother. 2006 Mar;57(3):573-6. Epub 2006 Jan 23.

PMID:
16431863
47.

Use of ribotyping to retrospectively identify methicillin-resistant Staphylococcus aureus isolates from phase 3 clinical trials for tigecycline that are genotypically related to community-associated isolates.

McAleese F, Murphy E, Babinchak T, Singh G, Said-Salim B, Kreiswirth B, Dunman P, O'Connell J, Projan SJ, Bradford PA.

Antimicrob Agents Chemother. 2005 Nov;49(11):4521-9.

49.

Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent oxyrase to standardize the test method.

Bradford PA, Petersen PJ, Young M, Jones CH, Tischler M, O'Connell J.

Antimicrob Agents Chemother. 2005 Sep;49(9):3903-9.

Supplemental Content

Loading ...
Support Center